Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharyn D Baker

Showing results (101-110 of 166) with videos related to

Pageof 17
Sort By:
Leukemia & Lymphoma|September 15, 2015
Clinical significance of in vivo cytarabine-induced gene expression signature in AMLJatinder K Lamba, Stanley Pounds, Xueyuan Cao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemiaFrancis J Giles, Guillermo Garcia-Manero, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumorsJianqing Lin, Jill Gilbert, Michelle A Rudek, et al.
Cancer Research Communications|August 22, 2025
Drug-drug interaction liabilities with BTK inhibitor TL-895Jack C Stromatt, Eman A Ahmed, Thomas Drabison, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 10, 2023
Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 MiceYang Li, Yasuhiro Kazuki, Thomas Drabison, et al.
Journal of the National Cancer Institute|April 14, 2011
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemiaShuiying Hu, Hongmei Niu, Hiroto Inaba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agentMichelle A Rudek, Ming Zhao, Nicola F Smith, et al.
Pharmaceutics|September 23, 2022
A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction LiabilitiesYang Li, Yan Jin, Hanieh Taheri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem DuplicationHiroto Inaba, Jolieke G van Oosterwijk, John C Panetta, et al.
Cancer Research Communications|March 2, 2026
Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine BioavailabilityNadeen Anabtawi, Thomas Drabison, Alexander F Ham, et al.
Pageof 17

Showing results (101-110 of 166) with videos related to

Sort By:
Pageof 17
Leukemia & Lymphoma|September 15, 2015
Clinical significance of in vivo cytarabine-induced gene expression signature in AMLJatinder K Lamba, Stanley Pounds, Xueyuan Cao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemiaFrancis J Giles, Guillermo Garcia-Manero, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumorsJianqing Lin, Jill Gilbert, Michelle A Rudek, et al.
Cancer Research Communications|August 22, 2025
Drug-drug interaction liabilities with BTK inhibitor TL-895Jack C Stromatt, Eman A Ahmed, Thomas Drabison, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 10, 2023
Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 MiceYang Li, Yasuhiro Kazuki, Thomas Drabison, et al.
Journal of the National Cancer Institute|April 14, 2011
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemiaShuiying Hu, Hongmei Niu, Hiroto Inaba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agentMichelle A Rudek, Ming Zhao, Nicola F Smith, et al.
Pharmaceutics|September 23, 2022
A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction LiabilitiesYang Li, Yan Jin, Hanieh Taheri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem DuplicationHiroto Inaba, Jolieke G van Oosterwijk, John C Panetta, et al.
Cancer Research Communications|March 2, 2026
Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine BioavailabilityNadeen Anabtawi, Thomas Drabison, Alexander F Ham, et al.
Pageof 17